The Regenerative Potential Of Young Versus Senescent Rabbit Adipose-Derived Mesenchymal Stem Cells And Their Impact On The Treatment Of Intervertebral Disc Degeneration

Therapeutic
Aging Pathway
Young adipose-derived mesenchymal stem cells show promise for regenerating intervertebral discs, while senescent (aged) cells are ineffective and may even worsen the condition.
Author

Gemini

Published

December 30, 2025

Back pain, often caused by the wearing down of the spinal discs (known as intervertebral disc degeneration), is a widespread issue. Current treatments often only address symptoms, but a promising area of research involves using special cells called mesenchymal stem cells (MSCs) to repair the damaged discs. These MSCs are like master cells that can develop into various cell types, including those found in the spinal discs.

Specifically, MSCs derived from fat tissue, known as adipose-derived mesenchymal stem cells (ADSCs), have shown a strong ability to transform into the cells that make up the central part of the spinal disc. However, when these cells are grown in a lab before being used in treatment, they can age, a process called senescence. Senescence means the cells lose their ability to divide and function effectively.

Recent research highlights a critical difference: young ADSCs are beneficial for regenerating spinal discs. In contrast, aged (senescent) ADSCs are not only ineffective in promoting disc repair but can actually make the disc’s condition worse. This finding is crucial for developing safe and effective stem cell therapies for intervertebral disc degeneration, emphasizing the importance of using young, healthy cells for treatment.


Source: link to paper